TRL1068 (calpurbatug)
Prosthetic Joint Infection (Biofilm)
Phase 1Active
Key Facts
About Trellis Bioscience
Trellis Bioscience is a private, pre-revenue biotech founded in 2018 that has developed the CellSpot™ platform for high-throughput discovery of native human monoclonal antibodies from healthy donors. The company's most advanced program, TRL1068, has demonstrated clinical proof-of-concept in a Phase 1 trial for reducing biofilm burden in prosthetic joint infections, a significant unmet medical need. Beyond infectious disease, Trellis has also discovered antibodies against immune checkpoint modulators and tumor-associated antigens for oncology, which are being advanced by partner Relevant Biosciences. The company is supported by non-dilutive funding from partnerships like CARB-X.
View full company profile